The latest update is out from Optiscan Imaging Limited ( (AU:OIL) ).
Optiscan Imaging Limited reported a 32% increase in revenue for the half-year ended December 2024, driven by higher sales from Carl Zeiss Meditec and increased R&D incentive income. Despite a decrease in net assets and a continued net loss, the company has accelerated its R&D efforts, which are expected to enhance its technology applications across various medical fields.
More about Optiscan Imaging Limited
Optiscan Imaging Limited operates in the medical imaging industry, focusing on developing and providing advanced imaging technologies. The company specializes in products and services related to precision surgery, pathology, telepathology, gastrointestinal, and veterinary applications.
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: €80.22M
For a thorough assessment of OIL stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com